European Journal of Dermatology


Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases Volume 28, numéro 1, January-February 2018


  • Figure 1

  • Figure 2

  • Figure 3
1 Division of Medical Oncology,
2 Institute of Pathology,
3 Institute of Radiology and Nuclear Medicine,
4 Division of Dermatology, Lucerne Cantonal Hospital and Cancer Center, 6000 Lucerne, Switzerland
* Reprints


Programmed cell death ligand 1 (PD-L1) is frequently expressed in cutaneous squamous cell cancer (CSCC) and preliminary data from an ongoing clinical trial suggest that programmed death receptor 1 (PD-1) checkpoint inhibitors may be useful to treat patients with metastatic non-melanoma skin cancer.